Business Insider

LIPOGEMS ANNOUNCES FIRST PATIENT ENROLLED IN THE U.S. ARISE STUDY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

ATLANTA, Jan. 13, 2023 /PRNewswire/ -- Lipogems, a clinical stage- global medical technology company, announces the first patient enrolled on January 13, 2023, in the ARISE U.S. FDA IDE study, which ...
Healio

FDA grants Lipogems IDE approval for clinical trial on treatment for knee OA

Please provide your email address to receive an email when new articles are posted on . The FDA has awarded Lipogems an investigational device exemption for a clinical trial on the company’s ...
Longview News-Journal

LIPOGEMS ANNOUNCES LAST PATIENT LAST VISIT FOR ARISE 1 KNEE OSTEOARTHRITIS TRIAL

ATLANTA, May 7, 2025 /PRNewswire/ -- Lipogems is proud to announce the completion of the ARISE I U.S. FDA IDE Study with the last patient's last visit successfully completed. This milestone marks the ...
ksn.com

LIPOGEMS ANNOUNCES FIRST PATIENT ENROLLED IN THE SECOND U.S. FDA IDE STUDY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

ATLANTA, April 5, 2024 /PRNewswire/ -- Lipogems, a clinical stage- global medical technology company, announces the first patient enrolled in the ARISE II U.S. FDA IDE research study, which aims to ...
KOIN 6

LIPOGEMS ANNOUNCES FIRST PATIENT ENROLLED IN THE U.S. ARISE STUDY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

"This is an exciting moment! We screened the first patient on December 30, 2022, and I'm proud to have enrolled the first patient for this trial," said Dr. Yogesh Mittal, Board-Certified and ...
WWLP-22News

LIPOGEMS ANNOUNCES LAST PATIENT ENROLLED IN THE U.S. FDA IDE ARISE STUDY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

ATLANTA, April 10, 2024 /PRNewswire/ -- Lipogems, a clinical stage- global medical technology company, announces it has completed enrollment in the ARISE I U.S. FDA IDE study, which aims to examine ...